Compare CRESY & APMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRESY | APMD |
|---|---|---|
| Founded | 1936 | 2017 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 804.3M | 895.5M |
| IPO Year | 1997 | 2026 |
| Metric | CRESY | APMD |
|---|---|---|
| Price | $11.46 | $18.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $15.86 | ★ $50.33 |
| AVG Volume (30 Days) | 201.5K | ★ 380.6K |
| Earning Date | 11-09-2026 | 11-03-2026 |
| Dividend Yield | ★ 5.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.96 | $136.17 |
| Revenue Next Year | $19.02 | N/A |
| P/E Ratio | $6.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.26 | $16.43 |
| 52 Week High | $14.21 | $35.29 |
| Indicator | CRESY | APMD |
|---|---|---|
| Relative Strength Index (RSI) | 47.97 | 43.61 |
| Support Level | $11.18 | N/A |
| Resistance Level | $11.74 | $30.22 |
| Average True Range (ATR) | 0.39 | 1.64 |
| MACD | -0.05 | 0.28 |
| Stochastic Oscillator | 39.58 | 45.47 |
Cresud SACIF y A is a Latin American agricultural firm producing basic commodities with a growing presence in Argentina, Brazil, and other countries through its investment in Brasilagro. It focuses on grains, sugarcane, and cattle farming, acquiring and developing agricultural properties for production or value appreciation, and occasionally selling appreciated land. It also leases land and offers agency and agro-industrial services. Operations are divided into two segments: agricultural business (production, land transformation and sales, corporate services) and urban properties and investments (shopping malls, offices, sales, developments, hotels, and related activities).
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).